Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27678380 | 0.87 | MERTK (0.44) | TOP2AMAPTMAPK1MEN1KMT2A | |
| SCHEMBL5510251 | 0.87 | TOP2A (0.48) | TOP2AMAPTMEN1KMT2APKM | |
| SCHEMBL5507273 | 0.83 | TOP2A (0.38) | TOP2AL3MBTL1MAPTPOLBMAPK1 | |
| SCHEMBL7431128 | 0.80 | HTT (0.60) | L3MBTL1MAPTPOLBMAPK1MEN1 | |
| SCHEMBL4924340 | 0.79 | HTT (0.56) | L3MBTL1MAPTPOLBMAPK1MEN1 | |
| SCHEMBL23777326 | 0.78 | TPSAB1 (0.56) | L3MBTL1MAPTPOLBMAPK1MEN1 | |
| SCHEMBL2417332 | 0.78 | TPSAB1 (0.56) | L3MBTL1MAPTPOLBMAPK1MEN1 | |
| SCHEMBL5505490 | 0.76 | KMT2A (0.65) | L3MBTL1MAPTPOLBMAPK1MEN1 | |
| SCHEMBL30503514 | 0.76 | BRD4 (0.47) | MEN1KMT2A | |
| SCHEMBL29475728 | 0.76 | BRD4 (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1968928-A | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | AVANIR PHARMACEUTICALS (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1753724-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | SIRCAR JAGADISH C | 2006-01-12 | — | — | US | disclosed |
| WO-2005123686-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | LDLR, NPC1L1, CETP | TOP2A 2540/4885L3MBTL1 2010/4885MAPT 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.